May 15, 2017
Otsuka Pharmaceutical Co., Ltd.
Otsuka Agree to Purchase New Share Allocation of TWO CELLS
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and TWO CELLS Company, Limited (TWO CELLS) entered into an agreement for Otsuka to purchase new shares issued by TWO CELLS. At the same time, the two companies will promote efforts to collaborate further in regenerative cell therapies based on Mesenchymal Stem Cells (MSCs) for the treatment of central nervous system disorders.*
Otsuka and TWO CELLS together will accelerate efforts to develop practical applications of MSC-derived regenerative therapies.
- Scope to include central nervous system disorders such as cerebral infarction, Alzheimer's disease, amyotrophic lateral sclerosis (except spinal cord injury).
About Mesenchymal Stem Cells
Mesenchymal Stem Cells (MSCs) are one type of somatic stem cell that have the ability to differentiate into various tissues or structures such as bone, cartilage, adipose (fat) and nerves.
Find out more about TWO CELLS at http://www.twocells.com/en/
Information in this news release was current as of the original release date.